Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday.
Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms.
For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization.
In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine.
That year 362 cases were recorded by the European Centre for Disease Prevention and Control.
Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said.
A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022.
Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated.
"The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute.
The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added.
The exact areas affected by the outbreak remains unclear.
But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said.
Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public.
They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease.
That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs.
ic-dl/giv
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
2025 Aromatherapy and Essential Oils Market Analysis Report: Holistic-Well-Being, Transparency, Sustainable Practices, Certifications and Claims, and AI-Powered Personalized Scents
The Global Aromatherapy and Essential Oils Market is poised for substantial growth, with a forecasted CAGR over 6%, driven by heightened well-being awareness and social media influence. Valued at over $8 billion in 2024, North America leads with 45% market share, fueled by holistic wellness trends. Asia-Pacific follows closely, propelled by demographic changes and Gen Z's health focus. Companies prioritizing personalized, natural solutions will thrive. The comprehensive report includes market size, revenue forecasts, trends, and more. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "2025 Aromatherapy and Essential Oils Market" report has been added to offering. The Global Aromatherapy and Essential Oils Market is set for consistent growth, with a projected CAGR exceeding 6% during 2024-2031 This expansion is driven by a growing emphasis on well-being, the rise of the she economy, the influence of social media, direct selling model and the increasing adoption of complementary and alternative medicine. The global market was valued over $8 billion in 2024. North America made up the largest portion of the global market with over 45% in revenues in 2024, followed by Asia Pacific with over 40% of revenues. The North American market is being driven by growing consumer interest in holistic wellness and natural remedies. As people become more focused on mental and emotional health, essential oils are being used for anxiety relief, stress management, and mindfulness. The rising awareness of sleep hygiene has also fueled demand for essential oil blends that promote relaxation and better sleep. Wellness brands are responding by offering more specialized products. The Asia-Pacific region is witnessing significant demographic and lifestyle shifts that are reshaping the wellness industry. Two primary factors driving this transformation are the aging population and the growing health-consciousness of younger generations like Gen Z. These changes are boosting the demand for products and services focusing on overall well-being. As European consumers continue to prioritize personalized and natural wellness solutions, the aromatherapy and essential oils market is poised for sustained growth. Companies that align their product lines with specific consumer needs, while emphasizing safety, sustainability, and quality, will remain competitive in this evolving landscape. Report Scope A comprehensive analysis of the Global Aromatherapy and Essential Oils Market for North America, Latin America, Europe, Asia-Pacific, and Rest of World, which includes market sizing, market share by competitor, drivers, restraints, regional trends and revenue forecasts to 2031. Essential oils are defined as natural oils, typically obtained by distillation, having the characteristic fragrance from the plant or other source extraction. Technically, aromatherapy means the use of aromas as therapy or the use of aromas for their healing properties. However, there is an increasing move to use the term 'essential oils' (which more accurately describes the existing market) as the therapeutic use of essential oils based on their aroma and properties, which includes internal use of the oils. For purposes of this research, only essential oils that are used for health and wellness and relaxation purposes via topical application, inhalation, diffusion, and ingestion have been included. The report includes the following information: Market Size, Growth Rate, Revenue Forecast (2024-2031) Revenue Share by Segment (distribution channel, product type, customer segment) Growth Drivers & Restraints Competitive Factors Industry Challenges Market Trends Regional Trends Pricing Trends Distribution Trends Regulatory Information Major Company Profiles Every report purchase comes with 1 hour of Analyst Inquiry Time for a phone call with the analysts. This can be used for strategic advice, consultation, or addressing issues in your business and linking them to a solution. Analyst Inquiry Time must be used within 45 days of report purchase. Key Topics Covered: 1. Research Scope, Methodology, Definition 2. Executive Summary Major Data Points - Global Revenue by Region, 2024 Revenue, Global, 2019-2024 3. Competitive Factors 4. Consumer Behavior 5. Market Drivers and Impact 6. Market Restraints and Impact 7. Global Trends Holistic-Well-Being Transparency Sustainable Practices Certifications and Claims AI-Powered Personalized Scents 8. Market Data - Global Total Market Revenue and Forecast Market Share by Company Distribution Share Analysis Market Share by Product Type 9. Competitive Landscape dOTERRA International, LLC Young Living Essential Oils, LC Melaleuca, Inc. 10. North America Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Market Data 11. Asia-Pacific Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - China, South Korea, Japan, and Australia Market Data 12. Europe Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - Germany, and United Kingdom Market Data 13. Latin America Major Data Point Consumer Behavior Market Drivers and Impact Market Restrains and Impact Market Trends Market Data 14. Market Data - Rest of the World Companies Featured doTERRA Young Living Melaleuca Inc. Ryohin Keikaku Co. Ltd. Plant Therapy Neal's Yard Remedies Jurlique Saje Natural Business Inc. Frontier Co-op (Aura Cacia) Rocky Mountain Oils Eden Botanicals Melaleuca Plant Therapy rareEssence Eden Gardens Essential oils Nature Packaged Swiss Just America Exotic Aroma Perfect Potion Essentials Quintis @aroma Primavera Life GmbH First Natural Brands (Tisserand) Farfalla Terra Gaia Florihana Neom well-being Aromatherapy Associates Absolute Aromas For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
27 minutes ago
- Yahoo
Finland's AIATELLA secures funds for AI cardiovascular imaging solutions
Finnish startup AIATELLA has raised €2m ($2.27m) in financing to develop and scale its cardiovascular imaging technology powered by AI. The investment will support the company in conducting clinical trials and further developing its ultrasound-based preventative screening tool, which can identify and quantify carotid artery narrowing within minutes. Nordic Science Investments spearheaded the funding round, with contributions from Specialist VC, Business Finland, and Harjavalta Ventures, among other investors. The Automated Image Measurement technology of the startup leverages images from ultrasound, computed tomography, and magnetic resonance imaging to analyse vascular imaging. This multimodal technology identifies abnormalities and quantifies changes over time in those at risk. It significantly reduces the time specialists spend on manual image measurements and documentation. As a result, clinicians can dedicate more time to patient care. AIATELLA is currently navigating the medical approval processes in several European and North American countries, including France, the US, and the UK. AIATELLA co-founder and CEO Jack Parker said: 'Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it's too late.' Initially applied to the aorta artery, AIATELLA's vision extends to encompass all blood vessels in the body with its technology. The startup noted that it is also developing a portable ultrasound-based screening technology for mass screening of individuals prior to the occurrence of symptoms. This approach aims to facilitate early detection of cardiovascular diseases, which are a major cause of mortality worldwide. The technology has already been employed in the UK and Finland at screening events, where it has helped identify potentially at-risk individuals. AIATELLA also aims to gather data on the presentation and progression of cardiovascular conditions across different sexes and ethnicities, as symptoms can vary widely among these different groups. "Finland's AIATELLA secures funds for AI cardiovascular imaging solutions" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and CB 2028 Allschwil, Switzerland – June 6, 2025Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period for the amended terms approved at the CB 2025 bondholder meeting of February 25, 2025 – during which no appeal was filed – it has published invitations to the next bondholder meetings for holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079). At the meetings, the company will propose changing the current terms of the CB 2025 and CB 2028 as part of the larger holistic restructuring, as announced in a press release on February 26, 2025, and an update published on May 21, 2025. To date, approximately 87% of the holders of the CB 2025 and 90% of holders of the CB 2028 have entered a legally binding lockup agreement in support of the holistic restructuring. Such bondholders have committed to vote in favour of the proposed amendments to the terms of the CB 2025 and CB 2028 at or before the meeting. The amendment of the terms of the CB 2025 and CB 2028 will be conditional on the consummation of the exchange offer, which is expected to be launched around or following the date of the bondholder meetings. Bondholders can access the invitations to the two bondholder meetings scheduled for Wednesday, June 25, 2025, including the terms of the resolution and additional information about the meeting, as well as a financial status report as of April 30, 2025, at the following links: and Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF